Mayne Pharma Group Limited (ASX:MYX) revealed that the New Drug Application for E4/DRSP for preventing pregnancy has been accepted for the US Food and Drug Administration review. The FDA is anticipated to complete review of this oral contraceptive pill in the H1 CY2021.
If approved, in the United States E4/DRSP would be the first contraceptive pill comprising of E4 and the first new estrogen launched for contraceptive use.
Post announcement on 24 June 2020, MYX quoted at A$0.385 climbed by 4.054% at AEST 12:26 PM.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.